SpaceX launched 23 Starlink satellites from Florida space force station
COCOA BEACH, Fla. (WFLA) — SpaceX held a Falcon 9 launch Sunday of 23 Starlink satellites from Cape Canaveral Space Force Station in Florida.
The launch was scheduled to begin at 10:09 p.m.
This was the 20th flight for the first stage of this mission. Previously the mission has launched Crew-5, GPS III Space Vehicle 06, Inmarsat I6-F2, CRS-28, Intelsat G-37, NG-20, TD7 and 12 others.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
Scientists Reveal Easy Three-Step Plan to Terraform Mars
Terraforming, the act of radically transforming a planet's climate and environment to make it suitable for human habitation, currently belongs to the realm of science-fiction. But it's possible, at least in theory, and the idea of terraforming our nearest candidate planet for off-world colonization, Mars, has captivated us for generations. But how would we even begin to pull off such a monumental feat of engineering? You can basically boil it down to three simple steps, argue the authors of a recent study published in the journal Nature Astronomy, who are encouraged by recent breakthroughs in several fields. "Thirty years ago, terraforming Mars wasn't just hard — it was impossible," lead author Erika DeBenedictis, CEO of Pioneer Labs, told "But new technology like Starship and synthetic biology have now made it a real possibility." The inclusion of Starship, the Elon-Musk owned SpaceX megarocket, may warrant some pushback, since it's faced several high-profile failures and is likely far from being completed. But the fact that a spacecraft of its scale is even being attempted at all is at least worth something. Alright, but assuming we can make the trip to the Red Planet, how do we turn it into something approaching a green one? Recent advances in Mars science suggest that the planet's vast stores of ice harbor enough water to form an ocean around 1,000 feet deep across 3,800,000 million square miles of the planet. And according to the study, these frigid seas-in-waiting could start melting with a temperature increase of at least 30 degrees Celsius. (There also appears to be subterranean oceans hidden beneath the surface.) So that's the first step. One way this could be achieved is by harnessing solar sails as mirrors to focus more light on the planet. This could be combined with dispersing aerosols in the atmosphere to accelerate the greenhouse effect, while techniques such as coating the Martian surface with particles called silica aerogels could help drive heating locally. Combined, the researchers estimated that the 30 degrees of warming could be achieved within the century. The next step involves getting a little help from tiny, anaerobic creatures that can survive the harshest environments: extremophiles. To serve as "pioneer species," we would likely have to genetically engineer these organisms so they can withstand Mars' low pressure and its cold temperatures, which swing wildly. As the planet's ancient water is liberated from its icy tombs, the first surfaces bodies of water will be extremely salty brines, which many microbes on Earth are capable of surviving, the authors write. Once these microbial critters take hold, they'd go to work reforming the planet's chemistry and laying the groundwork for a food-producing ecosystem. The final phase, however, is both the longest and most ambitious: shoring up the Martian atmosphere so that it can support diverse plant life and other organisms. To pull it off, terraformers would need to create at least a 100 millibar oxygen atmosphere, the authors write, or about a tenth of the Earth's average atmosphere at sea level. We could initially achieve this in large, 100-meter-tall domed habitats, they speculate. Outside of these habitats, the spread of plant life would passively contribute oxygen to the atmosphere — but this process on its own would take a millennium. We could artificially accelerate this, write the authors, by freeing oxygen from the melted water, but more research is needed to determine if the materials necessary to accomplish that are abundant on Mars so that they wouldn't be required to be imported from Earth in prohibitively large quantities. "We now know that Mars was habitable in the past, from data returned by the Mars rovers, so greening Mars could be viewed as the ultimate environmental restoration challenge," coauthor Edwin Kite, an associate professor at the University of Chicago, told As tempting as it would be for humanity to rise to the challenge, there are serious ethical and scientific questions to be raised about terraforming an entire planet, especially one that may have harbored life in the past, or perhaps still does. "If we decide to terraform Mars, then we will really change it in ways that may or may not be reversible," coauthor Nina Lanza, a planetary scientist at Los Alamos National Laboratory, told "Mars is its own planet and has its own history. When we terraform, then we effectively don't have the opportunity to study that anymore, and we may lose knowledge about how planets form and evolve." Of course, this remains speculative — it's serious speculation, but speculation all the same. For all the promising advances we've made, we still haven't proven we can send a tiny payload of samples back from Mars, or even demonstrate that our putative best shot of getting there, Starship, is spaceworthy. But, as they say: all in good time. More on Mars: Elon Musk's "Hubris and Arrogance" Are Ruining Our Chances of Actually Getting to Mars, Says Leading Expert
Yahoo
17 hours ago
- Yahoo
Elon Musk finally gets some good news from Jeff Bezos
Elon Musk finally gets some good news from Jeff Bezos originally appeared on TheStreet. The future of space transportation is looking increasingly complicated, as the falling-out between SpaceX CEO Elon Musk and U.S. President Donald Trump drags on. After Musk levied strong accusations against Trump and publicly stated he would not have been elected without his support, the president struck back with threats to cancel several SpaceX contracts. This leaves the company's short-term future in a precarious position, jeopardizing Musk's ambitions of colonizing Mars. 💵💰💰💵 Multiple space stocks responded to news of this conflict by surging, as investors looked to capitalize on SpaceX's questionable future. But one of Musk's primary rivals, a fellow privately held space exploration company, also recently revealed some less-than-positive news. Blue Origin, owned by Amazon founder Jeff Bezos, recently made an announcement regarding its plans for the future, which could be regarded as good news for SpaceX and Musk. While they both rose to fame founding companies that aren't direct competitors, Musk and Bezos are clear rivals in the space race. SpaceX and Blue Origin are both privately held and focused on space exploration and rocket is intended to be Musk's vehicle for colonizing Mars, while Bezos seems intent on cornering the space tourism market, which also includes rivals such as Richard Branson's Virgin Galactic. However, the two private companies are considered the leaders in the space exploration field. Blue Origin, though, recently reported what seems to be a setback. The company had been targeting Spring 2025 for the launch of its New Glenn rocket, a 320-foot-tall (98 meters) spacecraft with a reusable first stage, but now it has announced that the new launch will be held no earlier than (NET) August 15, 2025. CEO David Limp posted about to the delayed launch on X, revealing that one of the mission's key objectives would be to land and recover its booster. 'This will take a little bit of luck and a lot of excellent execution,' he states, adding that the company is on track to produce GS2s, referring to the second stage of the rocket. Following New Glenn's mostly successful January 2025 mission, the company hasn't indicated more progress toward further launches, even after its leaders initially set high expectations for its rocket launches. Now, as Ars Technica speculates, the August launch may be the only one Blue Origin completes this year. 'It is telling that Limp commented on the company tracking toward producing eight second stages, which would match the original launch cadence planned for this year,' the outlet notes. 'This likely is a fig leaf offered to Bezos, who, two sources said, was rather upset that Blue Origin would not meet (or even approach) its original target of eight launches this year.' More Elon Musk News: Elon Musk company reveals major leap forward The 'anti-Tesla' gives American buyers more good news Elon Musk's DOGE made huge mistakes with veterans' programs While Bezos may not be happy about this launch delay, it is excellent news for Musk, whose own company has seen three rockets explode so far this year. Even before the company's third mission spiraled out of control mid-flight, regulators had expressed concern about possible safety risks for people on the ground. There's no denying that both companies have faced challenges this year, as both race to outmaneuver each other and establish themselves as the leader of the space exploration market. Recent projections show that the space economy is expected to reach a $944 billion valuation by 2033, revealing a lot of room to run for problems plaguing both companies, though, raise the question of which one is better positioned to keep growing. SpaceX has launched several rockets this year, but its track record hasn't been encouraging, given the trend of explosions. And while Blue Origin has delayed its launch, that doesn't mean it will go well when it happens. On top of that, SpaceX still faces the possibility that it may lose out on lucrative federal contracts, unless Musk and Trump's feud is resolved soon. The zero-sum nature of financial markets means that for as long as its prospects appear uncertain, rivals will likely continue to gain. In this case, the list of companies that may benefit from SpaceX's uncertain future includes Blue Musk finally gets some good news from Jeff Bezos first appeared on TheStreet on Jun 11, 2025 This story was originally reported by TheStreet on Jun 11, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
18 hours ago
- Business Upturn
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52 (150 mg Q4W) Data further support barzolvolimab clinical benefit to patients with CSU HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company's Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1. The data were presented today by Dr. Martin Metz, Professor, Department of Dermatology and Allergy, Head of Translational Research and Deputy Head of Clinical Trials at Charité – Universitätsmedizin in Berlin, in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025. Celldex previously announced that the Phase 2 study in CSU met its primary and secondary endpoints at 12 weeks with clinically meaningful and statistically significant decreases in UAS7 (weekly urticaria activity score) compared to placebo across multiple dose groups, including improvements in quality of life and angioedema measurements, and demonstrated a favorable safety profile. The data presented today further support these results by demonstrating improvements in AAS7 (weekly angioedema activity score) and additional measures of angioedema control over the 52 week treatment period. AAS7 measures the frequency and intensity of angioedema episodes, where higher scores indicate increased angioedema activity. 'The majority of patients with severe CSU suffer with angioedema, which is often extremely painful and causes disfigurement, dramatically impacting quality of life,' said Diane C. Young, MD, Senior Vice President and Chief Medical Officer of Celldex Therapeutics. 'Consistent with previously reported clinical outcomes, we observed rapid, profound angioedema relief with barzolvolimab treatment and this benefit continued to improve over 52 weeks of therapy for patients. These data add to the unprecedented 76 week efficacy and safety data we presented yesterday at EAACI and continue to support barzolvolimab's potential to redefine the treatment landscape and meet the goals of CSU therapy—rapid, profound, durable complete response and improved quality of life across a broad patient population.' Summary of Key Findings: Patients on study had severe CSU. Over 70% of patients had a weekly urticaria activity score (UAS7) greater than 28 at baseline and reported very high rates of angioedema at baseline. Barzolvolimab demonstrated rapid, robust and durable improvements in angioedema symptoms over the treatment period. At Week 52, an 86% mean reduction from baseline was reported for 150 mg Q4W arm and an 82% reduction was reported for the 300 mg Q8W. Up to 77% of patients treated with barzolvolimab who had angioedema at baseline were angioedema free (AAS7=0) at Week 52. Patients treated with barzolvolimab were angioedema free up to 72% of the time over the 52 week treatment period. Up to 87% of patients reported clinically meaningful improvement ( > 8 point) in AAS7 at Week 52. 1 DermNet . About Barzolvolimab Barzolvolimab is a humanized monoclonal antibody that binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In certain inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease. Barzolvolimab is currently being studied in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), prurigo nodularis (PN), eosinophilic esophagitis (EOE) and atopic dermatitis (AD), with additional indications planned for the future. About the Phase 2 CSU Study The randomized, double-blind, placebo-controlled, parallel group Phase 2 study evaluated the efficacy and safety profile of multiple dose regimens of barzolvolimab in patients with CSU who remain symptomatic despite antihistamine therapy, to determine the optimal dosing strategy. 208 patients were randomly assigned on a 1:1:1:1 ratio to receive subcutaneous injections of barzolvolimab at 75 mg every 4 weeks, 150 mg every 4 weeks, 300 mg every 8 weeks or placebo during a 16-week placebo-controlled treatment period. After 16 weeks, patients then entered a 36-week active treatment period, in which patients receiving placebo or the 75 mg dose were randomized to receive barzolvolimab 150 mg every 4 weeks or 300 mg every 8 weeks; patients already randomized to the 150 mg and 300 mg treatment arms remained on the same regimen as during the placebo-controlled treatment period. After 52 weeks, patients entered a follow-up period for an additional 24 weeks. Barzolvolimab achieved the primary efficacy endpoint of the study—a statistically significant mean change from baseline to Week 12 in UAS7 (weekly urticaria activity score) compared to placebo at all dose levels. For additional information on this trial (NCT05368285), please visit About the Phase 3 Program Celldex is currently conducting a global Phase 3 Program for barzolvolimab in CSU, consisting of two Phase 3 trials (EMBARQ-CSU1; NCT06445023 and EMBARQ-CSU2; NCT06455202) designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment. The studies also include patients who remain symptomatic after treatment with biologics. Enrollment is underway. About Chronic Spontaneous Urticaria (CSU) CSU is characterized by the occurrence of hives or wheals for 6 weeks or longer without identifiable specific triggers or causes. The activation of the mast cells in the skin (release of histamines, leukotrienes, chemokines) results in episodes of itchy hives, swelling and inflammation of the skin that can go on for years or even decades. Current therapies provide symptomatic relief only in some patients. About Celldex Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit Forward Looking Statement This release contains 'forward-looking statements' made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as 'believes,' 'expects,' 'anticipates,' 'intends,' 'will,' 'may,' 'should,' or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159), in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under 'Risk Factors' in our annual report on Form 10-K and quarterly reports on Form 10-Q. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. Company ContactSarah CavanaughSenior Vice President, Corporate Affairs & Administration(508) 864-8337 [email protected]
